Transplant course and outcome
| Patient . | Engraftment . | Donor chimerism, % . | Day of DLI . | Acute GVHD . | Chronic GVHD . | Outcome . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| ANC* . | Platelets* . | Day 21 . | Day 100 . | 21 . | 42 . | 112 . | ||||
| 1 | 32 | 9 | 85 | 97 | + | + | − | No | N/E | PD, died on day 110 of disease |
| 2 | 14 | 0‡ | 100 | 100 | + | + | +2-153 | II2-155 (S, L) | Extensive | CR, died of GVHD on day 514 |
| 3 | 11 | 50 | 98 | 99 | + | + | − | II2-155 (S, G) | Limited | nCR, alive on day 490 |
| 4† | 13 | 14 | 97 | 100 | − | + | − | I (S) | Extensive | PR, died of GVHD on day 259 |
| 5 | 16 | 0‡ | 93 | 99 | + | + | + | I (S) | None | CR, alive on day 450 |
| 6 | 16 | 26 | 99 | 100 | + | + | − | II2-155(S) | Pulmonary | CR, alive on day 410 |
| 7 | 20 | 0‡ | 99 | 100 | + | + | +2-153 | No | Limited | PD, alive on day 370 |
| 8 | 19 | 30 | 100 | 100 | + | + | +2-153 | II2-155 (L, G) | Extensive | PR, alive on day 340 |
| 9 | 11 | 10 | 99 | 98 | + | − | − | II (S) | Limited | PD, alive on day 300 |
| 10 | 12 | 10 | 99 | 45 | − | + | − | No | N/E | PD, died on day 120 of disease |
| 11† | 11 | — | 99 | 100 | − | − | − | IV (L, G) | N/E | nCR, died of GVHD on day 119 |
| 12 | 12 | 0‡ | 99 | 100 | − | +2-153 | − | II2-155(L) | None | CR, alive on day 190 |
| 13 | 46 | — | 45 | < 1% | + | − | − | None | N/E | nCR, alive, autologous engraftment |
| 14 | 15 | 0‡ | 99 | 100 | + | +2-153 | − | II2-155(L) | None | VGPR, alive on day 150 |
| 15 | 25 | 35 | 55 | 99 | − | + | − | II2-155 (L, G) | None | VGPR, alive on day 120 |
| 16 | 10 | 11 | 100 | — | − | No | Too early | CR, alive on day 45 | ||
| Patient . | Engraftment . | Donor chimerism, % . | Day of DLI . | Acute GVHD . | Chronic GVHD . | Outcome . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| ANC* . | Platelets* . | Day 21 . | Day 100 . | 21 . | 42 . | 112 . | ||||
| 1 | 32 | 9 | 85 | 97 | + | + | − | No | N/E | PD, died on day 110 of disease |
| 2 | 14 | 0‡ | 100 | 100 | + | + | +2-153 | II2-155 (S, L) | Extensive | CR, died of GVHD on day 514 |
| 3 | 11 | 50 | 98 | 99 | + | + | − | II2-155 (S, G) | Limited | nCR, alive on day 490 |
| 4† | 13 | 14 | 97 | 100 | − | + | − | I (S) | Extensive | PR, died of GVHD on day 259 |
| 5 | 16 | 0‡ | 93 | 99 | + | + | + | I (S) | None | CR, alive on day 450 |
| 6 | 16 | 26 | 99 | 100 | + | + | − | II2-155(S) | Pulmonary | CR, alive on day 410 |
| 7 | 20 | 0‡ | 99 | 100 | + | + | +2-153 | No | Limited | PD, alive on day 370 |
| 8 | 19 | 30 | 100 | 100 | + | + | +2-153 | II2-155 (L, G) | Extensive | PR, alive on day 340 |
| 9 | 11 | 10 | 99 | 98 | + | − | − | II (S) | Limited | PD, alive on day 300 |
| 10 | 12 | 10 | 99 | 45 | − | + | − | No | N/E | PD, died on day 120 of disease |
| 11† | 11 | — | 99 | 100 | − | − | − | IV (L, G) | N/E | nCR, died of GVHD on day 119 |
| 12 | 12 | 0‡ | 99 | 100 | − | +2-153 | − | II2-155(L) | None | CR, alive on day 190 |
| 13 | 46 | — | 45 | < 1% | + | − | − | None | N/E | nCR, alive, autologous engraftment |
| 14 | 15 | 0‡ | 99 | 100 | + | +2-153 | − | II2-155(L) | None | VGPR, alive on day 150 |
| 15 | 25 | 35 | 55 | 99 | − | + | − | II2-155 (L, G) | None | VGPR, alive on day 120 |
| 16 | 10 | 11 | 100 | — | − | No | Too early | CR, alive on day 45 | ||
L indicates liver; S, skin; G, gastrointestinal; N/E, not evaluable; PD, progressive disease; DLI, donor lymphocyte infusion.
Days to absolute neutrophil count > 0.5 × 109/L; platelets > 20 × 109/L.
Mismatched donors.
No platelets were transfused.
Chemotherapy was given before cell infusion.
GVHD followed stem cell infusions.